CP
XERS icon

CenterBook Partners’s Xeris Biopharma Holdings XERS Stock Holding History

CenterBook Partners’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.24M Sell
1,248,621
-142,969
-10% -$948K 0.39% 63
2025
Q4 		$10.9M Buy
1,391,590
+693,386
+99% +$5.46M 0.53% 37
2025
Q3 		$5.68M Sell
698,204
-896,025
-56% -$5.95M 0.28% 88
2025
Q2 		$7.45M Buy
1,594,229
+1,122,154
+238% +$5.14M 0.41% 53
2025
Q1 		$2.59M Sell
472,075
-218,002
-32% -$880K 0.17% 159
2024
Q4 		$2.34M Sell
690,077
-2,791,929
-80% -$8.98M 0.14% 186
2024
Q3 		$9.92M Buy
3,482,006
+2,016,131
+138% +$5.18M 0.61% 37
2024
Q2 		$3.3M Sell
1,465,875
-77,998
-5% -$157K 0.21% 189
2024
Q1 		$3.41M Buy
1,543,873
+1,433,246
+1,296% +$3.71M 0.24% 164
2023
Q4 		$260K Buy
+110,627
New +$204K 0.03% 367

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CenterBook Partners's XERS Position: Q1 2026 in Review

CenterBook Partners reduced its Xeris Biopharma Holdings (XERS) stake by 10% in Q1 2026, selling an estimated $948K and leaving 1,248,621 shares worth $7.24M. The position accounts for 0.39% of the portfolio, ranked #63.

CenterBook Partners first reported a position in XERS in Q4 2023 and has held it in 10 quarters since. The position peaked at $10.9M in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • CenterBook Partners held 1,248,621 shares of Xeris Biopharma Holdings worth $7.24M as of Q1 2026.
  • CenterBook Partners sold 142,969 Xeris Biopharma Holdings shares in Q1 2026, an estimated $948K.
  • Xeris Biopharma Holdings made up 0.39% of CenterBook Partners's portfolio in Q1 2026, its #63 holding.
  • CenterBook Partners first reported a position in Xeris Biopharma Holdings in Q4 2023 and has held it in 10 quarters since.
  • CenterBook Partners's Xeris Biopharma Holdings position peaked at $10.9M in Q4 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on CenterBook Partners's 13F filing for Q1 2026, filed 5 May 2026.